Pharamcology/Therapeutics

Question 1

Alpelisib + Fulvestrant:
a. Molecular target/Treatment indication
b. Needed prior to initiating therapy

Answer 1

a. Alpelisib targets PIK3CA and used in treatment of metastatic triple-negative breast cancer
b. HbA1c - due to hyperglycemia risk

Question 2

Most common side effects associated with ALK inhibitors and first/second line therapy:
a. Alectinib
b. Brigatinib
c. Ceritinib
d. Lorlatinib

Answer 2

a. Alectinib - myalgias
b. Brigatinib – pneumonitis (start at a lower dose)
c. Ceritinib - GI toxicities
d. Lorlatinib - hyperlipidemia, personality changes

Question 3

Opiate Conversions from PO Morphine
a. IV Morphine 1 mg
b. IV Dilaudid 1 mg
c. PO Dilaudid 1 mg
d. Oxycodone 5 mg

Answer 3

Drug, MME Equivalent, Dosing
IV Morphine, 3, 10 mg
IV Dilaudid, 15, 1.5 mg
Hydromorphone PO, 5, 2 mg
Morphine, 1, 10mg
Oxycodone, 1.5, 6.6mg
Tramadol, 0.1, 100mg

NOTE: when switching between different opioids, the calculated dose-equivalent must be reduced to ensure safety by 25-50%